D
iabetes mellitus is the seventh leading cause of death in the United States. In addition, it is a leading cause of morbidity and leads to microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (coronary artery, cerebrovascular, and peripheral vascular disease) complications. Type 2 diabetes mellitus is the most common form of the disease (affecting 90% to 95% of persons with diabetes), with a prevalence of approximately 25.8 million people in the United States (1). Type 2 diabetes increases with age, and nearly 27% of people in the United States older than 65 years have diabetes (1) . In addition, because of increasing rates of obesity in the United States, the incidence and prevalence of diabetes mellitus are increasing substantially (1) . The costs associated with diabetes in the United States alone reached $174 billion in 2007 (2) .
Good management of type 2 diabetes with pharmacologic and nonpharmacologic therapies is important and includes patient education, evaluation for microvascular and macrovascular complications, treatment of glycemia, and minimization of cardiovascular and other long-term risks. In the United States, 11 unique classes of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperglycemia in type 2 diabetes; all of these medications vary in cost and risk (3) . Among people diagnosed with diabetes, most will receive more than 1 class of diabetes medication: 14% take both insulin and oral medication and 58% take oral medications only (2) .
The purpose of this American College of Physicians (ACP) guideline is to address the pharmacologic management of type 2 diabetes by comparing the effectiveness and safety of currently available oral pharmacologic treatment for type 2 diabetes. The target audience for this guideline includes all clinicians, and the target patient population comprises all adults with type 2 diabetes. These recommendations are based on a systematic evidence review by Bennett and colleagues (4) and an evidence report spon-sored by the Agency for Healthcare Research and Quality (AHRQ) (5) . The 2011 review expands on a 2007 AHRQ evidence report (6) , which discussed mortality, microvascular and macrovascular outcomes, intermediate outcomes, and adverse effects for drugs available until 2006. The 2011 report focuses on head-to-head comparisons and includes direct comparisons for monotherapy and dualtherapy regimens. Combination therapies with more than 2 agents were not included in the review. The 2011 report also includes evidence for more recently approved diabetes medications and excludes data on ␣-glucosidase inhibitors, such as acarbose (5) .
METHODS
The evidence report informing this guideline reviewed data for 11 FDA-approved, unique classes of drugs for the treatment of hyperglycemia in type 2 diabetes (Appendix Table 1 , available at www.annals.org). This guideline is based on a systematic evidence review that addressed thewas updated to December 2010 for long-term clinical outcomes (all-cause mortality, cardiovascular morbidity and mortality, nephropathy, neuropathy, and retinopathy). Reference lists, FDA medical reviews, European Public Assessment Reports, Health Canada Product Monographs, unpublished data from pharmaceutical companies, and public registries of clinical trials were also reviewed. Standardized forms were used for data abstraction, and each article underwent double review. Quality of randomized, controlled trials (RCTs) was assessed by using the Jadad criteria, and quality of observational studies was assessed as recommended in the Guide for Conducting Comparative Effectiveness Reviews (8, 9) . The I 2 statistic was used to determine study heterogeneity (10) . Further details about the methods and inclusion and exclusion criteria applied in the evidence review are available in the full AHRQ report (5) .
This guideline rates the recommendations by using the American College of Physicians guideline grading system, which is based on the GRADE system ( Table 1) . Details of the ACP guideline development process can be found in ACP's methods paper (11) . This guideline focuses on results that were statistically significant, and details on nonstatistically significant results are available in the full AHRQ report (5) . 
COMPARATIVE EFFECTIVENESS OF TYPE 2 DIABETES MEDICATIONS ON INTERMEDIATE OUTCOMES

HbA 1c Levels
Evidence was gathered from 104 head-to-head RCTs that varied from low to high quality and offered direct evidence from comparisons among various type 2 diabetes medications (5). 
Combination Therapy vs. Combination Therapy
One RCT showed that the combination of metformin plus a GLP-1 agonist (liraglutide) statistically significantly decreased HbA 1c levels by 0.34 to 0.60 percentage points in low-and high-dose combinations compared with metformin plus a DPP-4 inhibitor (sitagliptin) (low-quality evidence) (16) . A post hoc analysis of a small RCT showed that the combination of a thiazolidinedione plus a sulfonylurea decreased HbA 1c levels by 0.03 percentage point (P ϭ 0.04) more than did the combination of metformin plus a thiazolidinedione (low-quality evidence) (17) . All other combinations had similar efficacy in reducing HbA 1c levels (5).
Body Weight
Evidence was gathered from 79 head-to-head RCTs that varied from low to high quality and offered direct evidence from comparisons among various type 2 diabetes medications (5).
Monotherapy vs. Monotherapy
Pooled results showed that monotherapy with metformin resulted in more weight loss compared with thiazolidinediones (mean difference, Ϫ2. 
Combination Therapy vs. Combination Therapy
Pooled data showed that the combination of metformin plus a sulfonylurea was favored for weight compared with metformin plus a thiazolidinedione (mean difference, 0.9 kg [CI, 0.4 to 1.3 kg]; I 2 ϭ 0%; moderatequality evidence) (52-56). Pooled data also showed that the combination of metformin plus a sulfonylurea is favored over the combination of a thiazolidinedione and sulfonylurea (mean difference, Ϫ3.17 [CI, Ϫ5.21 to Ϫ1.13 kg]; I 2 ϭ 83%; moderate-quality evidence). Compared with the combination of metformin plus a sulfonylurea (glipizide), metformin plus a DPP-4 inhibitor (sitagliptin) statistically significantly reduced weight in 1 RCT (mean difference, Ϫ2.5 kg [CI, Ϫ3.1 to Ϫ2.0 kg]) (57), and the trend continued when the study was extended for another year (mean difference, Ϫ2.3 kg [CI, Ϫ3.0 to Ϫ1.6 kg]) (low-quality evidence) (58). Combination of metformin plus a GLP-1 agonist also resulted in greater weight loss compared with the combination of metformin plus a sulfonylurea, as shown in 2 RCTs (low-quality evidence) (49, 59).
Plasma Lipid Levels
Evidence was gathered from 74 head-to-head RCTs that varied from low to high quality and offered direct evidence from comparisons among various type 2 diabetes medications. Most diabetes medications had a small to moderate effect on lipid levels: 5 to 10 mg/dL for lowdensity lipoprotein (LDL) cholesterol, 3 to 5 mg/dL for high-density lipoprotein (HDL) cholesterol, and 10 to 30 mg/dL for triglycerides (5 (12, 14, 15) . Pooled data showed that monotherapy with sulfonylureas more effectively reduced LDL cholesterol than did pioglitazone (mean difference, 7.12 mg/dL [CI, 5.26 to 8.98 mg/dL]; I 2 ϭ 4%; low-quality evidence) (40, 68, 69), and 2 RCTs showed that rosiglitazone increased LDL cholesterol compared with sulfonylurea monotherapy (low-quality evidence) (37, 39).
Monotherapy vs. Combination Therapy.Compared with metformin monotherapy, combination of metformin with other agents did not show any benefit (5) .
Combination Therapy vs. Combination Therapy. The combination of metformin plus a sulfonylurea was favored over metformin plus a thiazolidinedione, as pooled data showed for rosiglitazone (mean difference, 13.5 mg/dL [CI, 9.1 to 17.9 mg/dL]; I 2 ϭ 0%; moderate-quality evidence) (54, 55, 70, 71) and a single RCT showed for pioglitazone (mean difference, 8.5 mg/dL; P ϭ 0.03; lowquality evidence) (56). The combination of metformin plus a sulfonylurea was also favored over the combination of pioglitazone plus a sulfonylurea, as reported in 2 RCTs (low-quality evidence) (72, 73) .
HDL Cholesterol Levels
Monotherapy vs. Monotherapy. Monotherapy with metformin was less effective than a thiazolidinedione (pioglitazone) at increasing HDL cholesterol levels (mean differ- (23, 40, 59, 68, 74, 75) and data from 2 RCTs for rosiglitazone (range in median between-group difference, 3.5 to 7.7 mg/dL; low-quality evidence) (37, 39). Two RCTs also showed that monotherapy with pioglitazone was favored over meglitinides (mean difference, 7 mg/dL; low-quality evidence) (75, 76 80 -82) , and 2 RCTs favored the combination of metformin plus pioglitazone over metformin monotherapy (46, 83) .
Combination Therapy vs. Combination Therapy. The combination of metformin plus a thiazolidinedione was favored over the combination of metformin and a sulfonylurea, as shown by pooled data for rosiglitazone (mean difference, 2.7 mg/dL [CI, 1.4 to 4.1 mg/dL]; I 2 ϭ 0%; moderate-quality evidence) (54, 55, 70, 71), data from 2 RCTs for pioglitazone (between-group differences ranged from 5.1 mg/dL [P Ͻ 0.001] to 5.8 mg/dL [P Ͻ 0.001]; low-quality evidence) (56, 84). Post hoc analysis in 1 RCT showed that the combination of metformin plus pioglitazone increased HDL cholesterol levels (2.3 mg/dL; P ϭ 0.009) compared with pioglitazone plus sulfonylurea (0.4 mg/dL; P ϭ 0.62) (low-quality evidence) (84) . Three RCTs found an increase in HDL cholesterol levels with the combination of pioglitazone plus a sulfonylurea compared with metformin plus a sulfonylurea (low-quality evidence) (72, 73, 84 (23, 40, 68, 69, 74, 75) . Two RCTs also favor pioglitazone over meglitinides for reducing triglyceride levels (75, 76) .
Monotherapy vs. Combination Therapy.Metformin monotherapy decreased triglyceride levels more than metformin plus a thiazolidinedione (rosiglitazone) (mean difference, Ϫ14.5 mg/dL [CI, Ϫ15.8 to Ϫ13.3 mg/dL]; I 2 ϭ 0%; high-quality evidence) (24, 44, 45, 47, 80 -82) . However, than with metformin monotherapy, combination therapy consisting of metformin plus a DPP-4 inhibitor (mean difference, 20.68 mg/dL [CI, Ϫ0.79 to 42.14 mg/dL]; low-quality evidence; P Ͼ 0.05) (14, 15, 47, 85) or metformin plus meglitinides (data from a single RCT: range of between-group differences, Ϫ17.8 to 8.9 mg/dL; P Ͻ 0.05 for the higher-dose nateglinide; low-quality evidence) (50) decreased triglyceride levels more than did metformin alone.
Combination Therapy vs. Combination Therapy. Two RCTs showed that the combination of metformin plus pioglitazone decreased triglyceride levels more than did metformin plus a sulfonylurea (between-group differences ranged from Ϫ10 mg/dL [P ϭ 0.30] to Ϫ24.9 mg/dL [P ϭ 0.045]; moderate-quality evidence) (56, 84). One small RCT found that metformin plus a GLP-1 agonist fared better than the combination of metformin plus rosiglitazone (between-group mean difference in triglyceride levels, 36.3 mg/dL; significance not reported; lowquality evidence) (86) . In addition, data from 4 RCTs showed that the combination of a thiazolidinedione (pioglitazone) plus a sulfonylurea decreased triglyceride levels more or increased triglyceride levels less than the combination of metformin plus a sulfonylurea (low-quality evidence) (72, 73, 84, 87) .
COMPARATIVE EFFECTIVENESS OF TYPE 2 DIABETES MEDICATIONS ON LONG-TERM CLINICAL OUTCOMES
A total of 66 studies (46 RCTs; duration, 12 weeks to 6 years) reported comparative effectiveness of oral diabetes medications on long-term outcomes. The mean age of participants ranged from 48 years to 75 years (5). It was difficult to draw conclusions about the comparative effectiveness of type 2 diabetes medications on all-cause mortality, cardiovascular morbidity and mortality, and microvascular outcomes because of low quality or insufficient evidence (4). Appendix Table 2 (available at www.annals.org) summarizes the findings and strength of evidence for long-term outcomes comparing various diabetes medications as monotherapy or combination therapy.
Mortality (All-Cause and Cardiovascular)
Five RCTs (30, 31, 33, 88, 89) and 11 observational studies (90 -100) were examined for all-cause mortality between metformin monotherapy and sulfonylurea monotherapy. These studies indicate that metformin was associated with lower all-cause mortality compared with sulfonylureas (low-quality evidence). Metformin was also favored over sulfonylureas for cardiovascular mortality (low-quality evidence), as evidenced by ADOPT (A Diabetes Outcome Progression Trial) (89) and 4 cohort studies (92, 94, 96, 101) , although 1 prospective cohort study showed a slightly higher cardiovascular mortality rate for metformin than for sulfonylurea monotherapy (94) .
Morbidity (Cardiovascular and Cerebrovascular)
Monotherapy with metformin was linked to lower cardiovascular morbidity than combination therapy for metformin plus sulfonylureas (low-quality evidence), as shown by 1 RCT (5% vs. 14% adverse cardiovascular events) (35) and 1 cohort study (adjusted incidence of hospitalization for myocardial infarction or coronary revascularization, 13.90 vs. 19.44 per 1000 person-years) (102) . Evidence for all other comparisons was insufficient or unclear (Appendix Table 2 ) (5).
Retinopathy, Nephropathy, and Neuropathy
There was moderate-quality evidence for nephropathy only for the comparison between pioglitazone and metformin. In the 2 studies that addressed this comparison, pioglitazone significantly reduced the urinary albumincreatinine ratio by 19% (25) and 15% (72) , whereas the ratio was unchanged in patients treated with metformin.
COMPARATIVE SAFETY OF TYPE 2 DIABETES MEDICATIONS
Appendix Table 3 (available at www.annals.org) summarizes the findings and strength of evidence for adverse effects among various diabetes medications as monotherapy or combination therapy.
Hypoglycemia
No particular monotherapy or combination therapy increased severe hypoglycemia (generally defined as hypoglycemia requiring assistance for resolution) compared with the other treatments (4).
Monotherapy vs. Monotherapy
Pooled results from monotherapy trials show that sulfonylureas increase the risk for mild to moderate hypoglycemia compared with metformin (odds ratio 
Combination Therapy vs. Combination Therapy
The combination of metformin plus a sulfonylurea increased the risk for hypoglycemia by about 6 times compared with the combination of metformin plus a thiazolidinedione (OR, 5.80 [CI, 4.30 to 7.70]; I 2 ϭ 0%; highquality evidence) (17, 52, 54, 56, 71) . One large RCT reported that metformin plus a thiazolidinedione resulted in fewer hypoglycemic events compared with a thiazolidinedione plus a sulfonylurea (0.05 vs. 0.47 event per 100 person-years of follow-up; low-quality evidence) (120) . Another study found more hypoglycemic symptoms in patients treated with the combination of metformin plus a sulfonylurea than with the combination of a thiazolidinedione plus a sulfonylurea (RR, 1.3 [CI, 0.9 to 2]; low-quality evidence) (121).
Other Adverse Effects
Evidence was insufficient to show any difference among the various type 2 diabetes medications on liver injury.
Evidence from 51 studies was evaluated to determine gastrointestinal effects (5) . Evidence examined from studies addressing these effects that compared metformin monotherapy with thiazolidinediones (high-quality evidence) (22, 24, 25, 89, 122) , sulfonylureas (moderate-quality evidence) (26, 27, 29 -33, 35, 66, 88, 89), DPP-4 inhibitors (moderate-quality evidence) (12, 14, 15) , or meglitinides (low-quality evidence) (115-118) report more gastrointestinal adverse effects with metformin. Trials comparing metformin monotherapy with combination metformin plus thiazolidinedione therapy (moderate-quality evidence) (24, 44 -47, 80 -82) or metformin plus sulfonylurea therapy (moderate-quality evidence) (27, 29 -33, 35, 49, 66, 88, 123) generally favored the combination therapy, although the metformin dosage was typically lower in the combination group, possibly accounting for this difference. One RCT reported more dyspepsia with a combination of metformin plus a meglitinide than with metformin plus a sulfonylurea (13% vs. 3%; low-quality evidence) (124) .
Clinical Guideline Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Two RCTs reported more diarrhea in combination treatment with metformin plus a sulfonylurea than with a thiazolidinedione plus a sulfonylurea (moderate-quality evidence) (72, 121) .
Although few studies reported on congestive heart failure, moderate-quality evidence from 5 observational studies favors metformin over sulfonylureas (98, 100, (125) (126) (127) , and moderate-quality evidence from 4 RCTs (39, 89, 103, 105) and 4 observational studies (98, 104, 125, 127, 128) favors sulfonylureas over thiazolidinediones. One 6-month observational study reported higher rates of heart failure with the combination of a thiazolidinedione plus a sulfonylurea (0.47 per 100 person-years) than with a thiazolidinedione plus metformin (0.13 per 100 personyears) (low-quality evidence) (120) . One RCT reported that the combination of a thiazolidinedione plus a sulfonylurea or metformin doubled the risk for heart failure compared with a sulfonylurea plus metformin (RR, 2.1 [CI, 1.35 to 3.27]; low-quality evidence) (129) .
Evidence was insufficient to show any difference among the various type 2 diabetes medications on macular edema.
One RCT identified 1 person with cholecystitis out of 105 patients treated with a thiazolidinedione compared with none of 100 patients treated with metformin (lowquality evidence) (22) . Another RCT identified 1 person with cholecystitis (n ϭ 280) treated with metformin monotherapy compared with no patients (n ϭ 288) treated with a combination of metformin plus a thiazolidinedione (low-quality evidence) (44). Low-quality evidence for pancreatitis came from 1 trial that reported 1 patient (n ϭ 242) with acute pancreatitis treated with a combination of metformin plus a sulfonylurea compared with no patients receiving metformin monotherapy (n ϭ 121) (49). The evidence was insufficient to show any difference in cholecystitis or pancreatitis with other monotherapies or combination therapies.
For bone fractures, high-quality evidence from 1 RCT showed more bone fractures with thiazolidinedione monotherapy than with metformin monotherapy (hazard ratio 
COMPARATIVE EFFECTIVENESS OF TYPE 2 DIABETES MEDICATIONS ACROSS SUBGROUPS OF ADULTS AGED 65 YEARS OR OLDER
Evidence was gathered from 28 studies (21 RCTs) that reported comparative effectiveness and safety data for subpopulations (defined by age, sex, or race; obesity, duration of diabetes, or geographic region; required medication dose; previous comorbid conditions) (5) . The evidence favoring one medication over another across subgroups is not clear because of lack of sufficient power in the included studies.
SUMMARY
The evidence shows that most diabetes medications reduced HbA 1c levels to a similar degree. Metformin was more effective than other medications as monotherapy as well as when used in combination therapy with another agent for reducing HbA 1c levels, body weight, and plasma lipid levels (in most cases). It was difficult to draw conclusions about the comparative effectiveness of type 2 diabetes medications on all-cause and cardiovascular mortality, cardiovascular and cerebrovascular morbidity, and microvascular outcomes because of low-quality or insufficient evidence.
High-quality evidence shows that the risk for hypoglycemia with sulfonylureas exceeds the risk with metformin or thiazolidinediones and that the combination of metformin plus sulfonylureas is associated with 6 times more risk for hypoglycemia than the combination of metformin plus thiazolidinediones. Moderate-quality evidence shows that the risk for hypoglycemia with metformin and thiazolidinediones is similar. Metformin is associated with an increased risk for gastrointestinal side effects. Thiazolidinediones are associated with an increased risk for heart failure, and both rosiglitazone and pioglitazone are contraindicated in patients with serious heart failure (132, 133).
The current evidence was not sufficient to show any difference in effectiveness among various medications across subgroups of adults.
RECOMMENDATIONS
Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence).
Initiation of oral pharmacologic therapy is an important approach to effective management of type 2 diabetes. There are no data on the best time to add oral therapies to lifestyle modifications; thus, to avoid an unacceptable burden on patients, other complicating factors should be considered, such as life expectancy of the patient, presence or absence of microvascular and macrovascular complications, risk for adverse events related to glucose control, and patient preferences (134) . The goal for HbA 1c should be based on individualized assessment of risk for complications from diabetes, comorbidity, life expectancy, and patient preferences. An HbA 1c level less than 7% based on individualized assessment is a reasonable goal for many but not all patients.
Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence).
The effectiveness, adverse effect profiles, and costs of various oral pharmacologic treatments vary. Metformin is more effective than other pharmacologic agents in reducing glycemic levels and is not associated with weight gain. In addition, metformin aids in decreasing weight and reduces LDL cholesterol and triglyceride levels. Metformin was also associated with slightly lower all-cause mortality and cardiovascular mortality compared with sulfonylureas. Finally, metformin is associated with fewer hypoglycemic episodes and is cheaper than most other pharmacologic agents. Therefore, unless contraindicated, metformin is the drug of choice for patients with type 2 diabetes, in addition to lifestyle modification. Metformin is contraindicated in patients with impaired kidney function, decreased tissue perfusion or hemodynamic instability, liver disease, alcohol abuse, heart failure, and any condition that might lead to lactic acidosis. 
Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; high-quality evidence).
• Good management of type 2 diabetes with pharmacologic and nonpharmacologic therapies is important and includes patient education, evaluation, and self-management, for microvascular and macrovascular complications, treatment of hyperglycemia, and minimization of cardiovascular and other long-term risk factors.
• Nonpharmacologic therapy includes dietary modifications, regular exercise, lifestyle modifications, and weight loss.
• Initiation of pharmacologic therapy is an important approach for the effective management of type 2 diabetes when weight loss and/or lifestyle modification fails.
• Metformin monotherapy was more effective in decreasing glycemic levels than other monotherapies, as well as in combination therapy with a second agent. In addition, metformin has the advantage of reducing body weight and improving plasma lipid profiles (in most cases).
• Although combination therapy more effectively reduces hemoglobin A 1c levels, it is also associated with more adverse events.
Clinical Guideline Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Physicians and patients should discuss adverse event profiles before selecting a medication. Compared with baseline values, most diabetes medications (metformin, thiazolidinediones, and sulfonylureas) reduced baseline HbA 1c by about 1 percentage point 3 or more months after the initiation of treatment. For adverse effects, metformin is associated with an increased risk for gastrointestinal side effects, sulfonylureas and meglitinides are associated with an increased risk for hypoglycemia, and thiazolidinediones are associated with an increased risk for heart failure (with no conclusive evidence for an increase in ischemic cardiovascular risk). However, in comparing the effectiveness of various agents, the evidence shows that metformin is the most efficacious agent as monotherapy and in combination therapy.
Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; high-quality evidence).
All dual-therapy regimens were more efficacious than monotherapies in reducing the HbA 1c level in patients with type 2 diabetes by about 1 additional percentage point. Combination therapies with more than 2 agents were not included in the evidence review. No good evidence supports one combination therapy over another, even though some evidence shows that the combination of metformin with another agent generally tends to have better efficacy than any other monotherapy or combination therapy. However, combination therapies are also associated with an increased risk for adverse effects compared with monotherapy. Generic sulfonylureas are the cheapest second-line therapy; however, adverse effects are generally worse with combination therapies that include a sulfonylurea.
Although this guideline addresses only oral pharmacological therapy, patients with persistent hyperglycemia despite oral agents and lifestyle interventions may need insulin therapy.
See Figure 1 for a summary of the recommendations and clinical considerations.
ACP BEST PRACTICE ADVICE
On the basis of the evidence reviewed in this paper, ACP has found strong evidence that in most patients with type 2 diabetes in whom lifestyle modifications have failed to adequately improve hyperglycemia, oral pharmacologic therapy with metformin (unless contraindicated) is an effective management strategy. It is cheaper than most other pharmacologic agents, has better effectiveness, and is associated with fewer adverse effects; of note, it does not result in weight gain (Figure 2) . 
